Sarepta turns up after Endpoints updates on FDA official’s view on study need

Shares of Sarepta (SRPT) have come off their lows and moved into positive ground after an editor at Endpoints News updated on the publications discussions with an unnamed senior official at the FDA about Elevidys. Earlier this morning, Endpoints had reported that an FDA official said Sarepta would have to conduct new studies to get Elevidys back on the market. In a post to X this afternoon, Zachary Brennan, Senior Editor at Endpoints News, stated: “Updated: In a follow-up conversation on the safety study, the senior official said Sarepta could make a change to the dosing or manufacturing, and test it on the next 10 or 12 boys, and show the liver-related issues were improved” Heading into the close, shares of Sarepta are up fractionally to $13.34.